This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Asia: Oligonucleotide & Peptide Therapeutics
26-28 Feb, 2025
Westin Miyako KyotoKyoto, Japan

Chris Oswald
Founder, Owner, and Principal Consultant at Coswald Consulting LLC
Speaker

Profile

Chris is an independent consultant specializing in CMC related activities. His experience spans from developing oligo related analytical methods in the laboratory, to managing a commercial QC laboratory, and then into being the manufacturing plant manager for Agilent Technologies. These roles have provided him exposure to many CMC strategies that have been successfully utilized for clinical, pre-commercial, and commercial oligonucleotides in both the drug substance and drug product arenas. Chris also has a wide range of experience in facility buildouts, both new and appended, allowing exposure and understanding of the many unseen, as well as the very visible, parameters related to facility, equipment, process, and personnel that are necessary to align and control to ensure a successful and robust scaleup / technical transfer.

Agenda Sessions

  • Large Scale Manufacturing: Challenges and Solutions

    9:10am
  • Panel Discussion and Q&A with Workshop Speakers

    12:00pm
  • Drug Substance and Drug Product CMC Strategies for Start-Ups and Smaller Companies

    1:45pm